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Introduction. 24-hour ambulatory blood pressure monitoring (ABPM) plays an important role in assessing cardiovascular
prognosis, through presence or absence of ABPM-related prognostic features. Objectives. To study relationship between 24-hour
ABPM and cardiovascular outcomes in patients from Chesterﬁeld Royal Hospital. Material and Methods.O v e r1 2m o n t h sf r o m
the 1st of August 2002, 1187 individuals had 24-hour ABPM performed. Cardiovascular outcomes were studied in a subset
(297) of the original cohort, made up by every 4th consecutive subject. The following ABPM-related prognostic features were
studied—high day time systolic and diastolic BP (≥135, ≥85mmHg), high night time systolic and diastolic BP (≥120mmHg,
≥75mmHg),absence ofnocturnal dip (≤10%fall in nighttime SBP),high early morningSBP(≥140mmHg), and morningsurge
(≥20/15mmHg).Thecardiovascularoutcomesstudied inthefourthtableincludedfatalandnonfatalMI,newdiagnosisofangina,
acutecoronarysyndrome,suddencardiacdeath,cardiacarrhythmias,acuteLVF,cerbrovascularevents,peripheralvasculardisease,
abdominal aortic aneurysm, and CKD stage 3 or above. Results. Over a followup period of 2015 ± 116 days (1720–2305 days) 82
cardiovascular events occurred in 61 subjects. Cardiac arrhythmias were the most common CV outcome (34 events) followed by
cerebrovascular events (15). Statistically signiﬁcant associations found were between cerebrovascular events and absent nocturnal
dip ≤10%(P = .05)andhighdaytimeDBP(P = .029),peripheralvasculardiseaseandmorningsurge ≥20/15mmHg(P = .014),
cardiac arrhythmias and high day time and night time DBP (P = .009 and .033, resp.). Conclusion. Signiﬁcant associations were
found between cerebrovascular events and absent nocturnal dip ≤ 10% and high day time DBP, peripheral vascular disease and
morningsurge ≥ 20/15mmHg, cardiac arrhythmias and high day time and night time DBP.
1.Introduction
24-hour ABPM plays an important role in determining
cardiovascular prognosis and has been shown to be a
better predictor of cardiovascular morbidity and mortality
as compared to oﬃce blood pressure measurements [1–3].
2.Objectives
The objective was to study the relationship between 24H
ABPM and cardiovascular outcomes in patients from
Chesterﬁeld Royal hospital. It was a retrospective observa-
tional study based on review of clinical case notes.
3.Materialand Methods
Over 12 months from the 1st of August 2002, 1187
individuals had 24-hour ABPM performed. These individ-
uals represented a typical spectrum of patients attending
for 24H ABPM with blood pressure at diﬀerent stages
and with varying durations of hypertension. Cardiovas-
cular outcomes were studied in a subset (297) of the
original cohort, made up by every 4th consecutive sub-
ject.
The inclusion criteria were as follows.
(i) Individuals must have one of the recognized indica-
tions for 24-hour ABPM, as outlined in Table 1.2 International Journal of Hypertension
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Figure 1: Distribution of number of CV outcomes in 61 patients.
(ii) Every 4th consecutive patient was entered into the
study, giving a total of 297, patients. Table 2 outlines
demographics and blood pressure criteria between
the original cohort and the study cohort.
The exclusion criteria were as follows.
(i) Clinical case notes to study prognostic information
were not available from 52 subjects and they were
excluded leaving 245 patients.
The following ABPM-related prognostic features were stud-
ied (Table 3) high day time systolic and diastolic BP
(≥135, ≥85mmHg), high night time systolic and diastolic
BP (≥120mmHg, ≥75mmHg), absence of nocturnal dip
(≤10% fall in night time SBP), high early morning SBP
(≥140mmHg), and morning surge (≥20/15mmHg rise in
the ﬁrst two morning readings from 7 AM as compared
to average night time BP) [4]. The cardiovascular out-
comes studied (Table 4) included fatal and nonfatal MI,
new diagnosis of angina, acute coronary syndrome, sudden
cardiac death, cardiac arrhythmias, acute LVF, cerebrovas-
cular events, peripheral vascular disease, abdominal aortic
aneurysm, and CKD stage 3 or above.
4.Results
Overa followup period of 2015±116 days (1720–2305days)
82 cardiovascular events occurred in 61 subjects. Cardiac
arrhythmias were the most common CV outcome (34
events) followed by cerebrovascular events (15). Statistically
signiﬁcant associations found were between cerebrovascular
events and absent nocturnal dip ≤ 10% (P = .05) and
high day time DBP (P = .029), peripheral vascular disease
and morning surge ≥ 20/15mmHg (P = .014), cardiac
arrhythmias and high day time and night time DBP (P =
.009 and, 033, resp.). Age and gender did not have any
statistical associations with the outcomes.
Table 1
Indications for 24-hour ABPM
Borderline hypertension
Variable clinic blood pressure
Suspected white coat hypertension
Suspected white coat eﬀect
Resistant hypertension
Hypertension in pregnancy
Hypertension in elderly patients
Evaluation of symptoms suggesting postural hypotension
Evaluationofsymptomssuggestingdruginducedhypotension
Blood pressure evaluation in patients with the suspected or
proven autonomic dysfunction
As an overall guide to hypertension treatment
As a prognostic cardiovascular tool
5.Discussion
In this study, cardiac arrhythmias were the most commonly
observed event accounting for 13.9% of the total events.
Atrial ﬁbrillation was the most common cardiac arrhythmia
seen in 14/38 (52.9%) patients with cardiac arrhythmias,
followed by symptomatic ventricular ectopics in 13 subjects
(38.2%) and supraventricular tachycardia and sinoatrial
pause in 1 patient each.
Atrial ﬁbrillation is being recognised as a common
problem in patients with hypertension. It has been shown to
be associated with systolic hypertension [4] and high pulse
pressure [5]. Atrial ﬁbrillation may complicate even mildly
raised blood pressure, and it would be reasonable to assume
that there is no threshold below which the risk of atrial
ﬁbrillation isnotincreased [6].To thebest ofourknowledge,
our study is the ﬁrst one to show an increased risk of atrial
ﬁbrillation with high day time and night time diastolic blood
pressure. Having said that, one of the recent Japanese studies
has shown that control of both systolic and diastolic blood
pressure is important in reducing risk of new onset atrial
ﬁbrillation [7].International Journal of Hypertension 3
Table 2: Comparison of cohorts 1 and 2.
Cohort 1: 1187 patients Cohort 2: 245 patients Statistical signiﬁcance
Age 59.13yrs ± 13.9 60.1yrs ± 13.6 NS
N % N %
Male 547 46.1 107 43.7 NS
Female 640 53.9 138 56.3
Adverse features N % N %
High PP ≥ 50mmHg 736 62.0 161 65.7 NS
High DSBP ≥ 135mmHg 703 59.2 146 59.6 NS
High DDBP ≥ 85mmHg 515 43.4 101 41.2 NS
High NSBP ≥ 120mmHg 639 54.0 138 56.3 NS
High NDBP ≥ 75mmHg 404 34.0 83 33.9 NS
Absent ND ≤ 10% 677 57.0 134 54.7 NS
High EM SBP ≥ 140mmHg 396 33.4 74 30.2 NS
High MS ≥ 20/15mmHg 552 46.5 106 43.3 NS
No. adverse features N % N %N S
0 63 5.3 13 5.3 NS
1 114 9.6 22 9.0 NS
2 177 14.9 35 14.3 NS
3 168 14.2 43 17.6 NS
4 176 14.8 35 14.3 NS
5 182 15.3 37 15.1 NS
6 151 12.7 30 12.2 NS
7 119 10.0 23 9.4 NS
8 37 3.1 7 2.9 NS
Adverse Features groups N % N %
0–2 354 29.8 70 28.6
3–5 526 44.3 115 46.9 NS
6–8 307 25.9 60 24.5
There was no signiﬁcant diﬀerence between the two cohorts.
(Oneway Anova was used for comparing cohort 1 and 2 ages; cross-tabulation with chi-square Test was used to compare adverse features; no. of adverse
features and adverse features groups and gender).
Table 3: List of adverse prognostic features noted on 24-hour
ABPM.
Adverse features Values∗
High pulse pressure ≥50 mmHg
High day systolic BP ≥135 mmHg
High day diastolic BP ≥85 mmHg
High night systolicBP ≥120 mmHg
High night diastolic BP ≥75 mmHg
Absent nocturnal dip ≤10 %
High early morning systolic BP ≥140 mmHg
High morning surge ≥20/15 mmHg
∗K. Madin and P. Iqbal (PMJ 2006)
Over the years a variety of other risk factors for atrial
ﬁbrillation have been identiﬁed such as large left-atrial size,
obesity, thyrotoxicosis, and high alcohol. Our study does not
take into account these risks factors.
The exact mechanism for atrial ﬁbrillation in hyperten-
sive subjects is not understood but is believed to be related
to left ventricular hypertrophy and an increase in left-atrial
size [8], left-atrial ﬁbrosis secondary to high systolic blood
pressure [9] and changes in autonomic tone with higher in-
treatment heart rate on serial ECGs [10].
Atrial ﬁbrillation is an important cardiovascular risk
factor for thromboembolic cardiovascular disease and adds
to the existing risk from hypertension itself. Treatment of
hypertension exclusively with ACE inhibitors, angiotensin-
II-receptor blockers, and beta blockers was shown to be
associated with a lower risk of developing atrial ﬁbrillation
than current exclusive therapy with calcium-channel
blockers [11].
In summary, our study shows that diastolic hypertension
plays an important role in leading to cardiac arrhythmias,
in particular atrial ﬁbrillation, and should be treated as
vigorously as systolic hypertension.
The study’s main limitation is that it did not take into
account presence or absence of other cardiovascular risk
factors, such as diabetes mellitus, smoking, hyperlipidaemia,
or family history, and has relied entirely on blood pressure
criterias. The authors would like to acknowledge that this
may have had bearing on some of the ﬁndings.4 International Journal of Hypertension
Table 4
List of CV outcomes, detected on retrospective case notes review.
Non-fatal ST segment elevated MI (ESC/ACC 2000)
Non-fatal non-ST segment elevated MI (ACC/AHA2007)
Non-fatal acute coronary syndrome
New diagnosis of angina pectoris (typical history and positive treadmill cardiac test)
Fatal ST segment elevated MI (ESC/ACC 2000)
Fatal non-ST segment elevated MI
Fatal acute coronary syndrome
Sudden cardiac death (ACC/AHA 2006)
Cardiac arrhythmias (resting or ambulatory ECG documented evidence of any supraventricular and ventricular arrhythmias)
Acute left ventricular failure (typical clinical history backed by chest X-ray ﬁnding)
Fatal or non-fatalcerebrovascular event (typical clinical history and CT/MRI ﬁndings)
Renal failure (CKD stage 3 or above, developing during the followup period, according to K/DOQI 2002)
Peripheral vascular disease, typical symptoms supported by bilateral lower limb arterial Doppler
Fatal or non-fatalabdominal aortic aneurysm ≥ 4cm on abdominalultrasound done in the followup period
Table 5
82-Cardiovascular outcomes in 61
patients
Frequency
Myocardial infarction 6 (2.4%)
Acute coronary syndrome 3(1.2%)
New diagnosis of angina pectoris 4(1.6)
Sudden cardiac death 0
Cardiac arrhythmias 34 (13.9%)
Acute left ventricular failure 0
Fatal or non-fatal cerebrovascular
event
15 (6.5%)
Peripheral vascular disease 5( 2 % )
Fatal or non-fatal abdominalaortic
aneurysm
1 (0.4%)
Renal failure (CKD ≥ stage 3) 14 (5.7%)
Statistically signiﬁcantassociations
(Fisher exact test)
Cerebrovascular events and absent
nocturnal dip ≤ 10%
P = .50
Cerebrovascular events high day time
DBP
P = .029
Peripheral vascular disease and
morning surge ≥ 20/15mmHg
P = .014
Cardiac arrhythmias and high day
time
P = .009
Cardiac arrhythmias and night time
DBP
P = .033
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